eGene Inc. announces its strategic full service distribution alliance with Prisma Biotech of Taiwan
eGene, Inc., which is in the business of developing, manufacturing, and marketing analytical systems and reagents for the global genotyping market, reports today on its alliance.
Udo Henseler Ph.D., CEO, said, “We are pleased to announce our strategic full service distribution alliance in Taiwan with Prisma Biotech (http://www.prismabiotech.com.tw ), a highly regarded and successful full service distributor in the broader field of biotechnology products. Prisma Biotech’s mission is to associate with innovative companies for distribution of Research and Advanced Diagnostic products and services, and supporting customers with exceptional service and technical support when introducing new frontier Lab techniques and methods.”
Kevin Tseng, President & CEO at Prisma Biotech, stated, “We have been impressed by the highly innovative and cost effective Micro-Fluidic technology platform offered by eGene’s HDA-GT12(TM) multichannel capillary electrophoresis system for a broad range of applications. We believe that it could represent the real breakthrough and the affordable solution for most medium sized Laboratories involved with DNA separation and genotyping. The alliance with Prisma Biotech represents a decisive strengthening and important rounding out of our marketing program.”
About eGene, Inc.
eGene, Inc. offers a low cost, micro-fluidic, miniaturized, digital Genotyping system, which is critical to the present and future of microbial and biological materials testing applications. The Company’s product detects, quantifies, identifies and characterizes micro-organisms at unprecedented specificity and sensitivity, and automates routine and non-routine laboratory and industrial procedures critical to product safety, quality and productivity. For more information, visit eGene’s web site at: www.egeneinc.com or view its reports that have been filed with the Securities and Exchange Commission that are contained in the Edgar archives at www.sec.gov .
Certain matters discussed in this news release may be forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risk of dependence on markets, competition as well as other uncertainties, and is subject to all the risks of an early biotechnology business enterprise.
